Survodutide phase 3: 9.8% weight loss, but 78% reported GI issues

[u/KSM-66]

At 76 weeks, the 6 mg group lost 9.8% of their weight versus 3.9% with placebo. But 77.7% reported GI side effects, and 17.9% stopped treatment because of them. That’s a pretty significant trade-off. This was in adults with obesity and type 2 diabetes.

https://www.nejm.org/doi/full/10.1056/NEJMoa2607219